Wordt geladen...
Addition of bevacizumab to preoperative chemotherapy for colorectal liver metastases does not increase perioperative morbidity and mortality
AIM: Patients with colorectal liver metastases (CRLM) benefit from liver resection. Bevacizumab is commonly used in these patients resulting in a greater number of patients receiving an operation for a potentially curative liver resection, with initially unresectable liver metastases. Our purpose wa...
Bewaard in:
| Gepubliceerd in: | Hepat Oncol |
|---|---|
| Hoofdauteurs: | , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Future Medicine Ltd
2014
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6095412/ https://ncbi.nlm.nih.gov/pubmed/30190972 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/hep.14.17 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|